Michael Fossel

Michael Fossel

Company: Telocyte

Job title: President & Founder


Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug 4:00 pm

Discussing criteria determining which drugs to progress for CDx selection to inform clinical strategy and investment plan Changing requirements to implement a diagnostic in the early phase clinical trial Vs what’s needed for later approval Engaging different arms of the business, to build trust for CDx development Pre-empting bottlenecks in Dx development to de-risk investmentRead more

day: Day One

“Everything Works in Mice, Nothing Works in Humans”: How a Unified Systems Model can Enable Therapeutic Success 2:00 pm

Current interventions fail to alter the clinical vectors of agerelated neurodegenerative diseases, e.g., Alzheimer’s A unified systems model must encompass animal and human pathology (both histological and clinical), upstream risk factors (e.g., genetic risk factors, TBI, etc.), and downstream biomarkers (e.g., amyloid plaque, tau tangles, mitochondrial dysfunction, etc.) A cell senescence model is consistent with…Read more

day: Track A - Day 1 PM

Novel Models to Progress from Preclinical

1:36 pm

Read more

day: Track A - Day 1 PM

Moving the Needle in Immuno-Oncology

10:05 am

Read more

day: Track A - Day 1 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.